- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
R2 Technology registers for IPO
Privately held R2 Technology has taken the first step toward going public. The pioneer of computer-assisted diagnosis has filed a registration statement with the Securities and
Privately held R2 Technology has taken the first step toward going public. The pioneer of computer-assisted diagnosis has filed a registration statement with the Securities and Exchange Commission for an initial public offering of common stock. Net proceeds will be used for general corporate purposes, including working capital, R&D, sales and marketing, clinical and regulatory studies, and capital expenditures. A portion may also be used to acquire or invest in complementary businesses, products, and technologies. R2 develops, manufactures, and sells proprietary medical systems to assist radiologists in the detection of cancer. The company's ImageChecker CAD system analyzes medical images, marking features that may indicate cancer. Prior to the registration, the company secured $14 million in venture capital financing. That round brought the total of VC financing to $76 million since the company was incorporated in 1993.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
